Table 2. Significant pathways by preranked gene set enrichment analysis on all genes prioritized by the predicted total scores.

Name	Size	ES	NES	FDR P-value
Neuroactive ligand receptor interaction	270	0.67	2.87	<1.0E-05
Calcium signaling pathway	176	0.58	2.40	<1.0E-05
Hedgehog signaling pathway	56	0.66	2.32	<1.0E-05
Cytokine cytokine receptor interaction	260	0.54	2.29	<1.0E-05
Cell adhesion molecules cams	131	0.58	2.28	<1.0E-05
Basal cell carcinoma	55	0.66	2.27	<1.0E-05
Axon guidance	128	0.56	2.23	<1.0E-05
Autoimmune thyroid disease	50	0.62	2.14	9.15E-05
Melanogenesis	101	0.55	2.13	8.14E-05
Maturity onset diabetes of the young	25	0.71	2.13	7.32E-05
Olfactory transduction	389	0.48	2.11	1.40E-04
Arrhythmogenic right ventricular cardiomyopathy	74	0.57	2.07	2.55E-04
Ecm receptor interaction	84	0.54	1.97	7.09E-04
Gap junction	89	0.52	1.96	7.73E-04
Dilated cardiomyopathy	90	0.51	1.93	1.03E-03
Proximal tubule bicarbonate reclamation	23	0.65	1.93	1.06E-03
Long term depression	70	0.52	1.92	1.10E-03
Hypertrophic cardiomyopathy hcm	83	0.51	1.90	1.42E-03
Melanoma	71	0.52	1.89	1.47E-03
Allograft rejection	35	0.58	1.86	1.84E-03
Type I diabetes mellitus	41	0.57	1.86	1.86E-03
Vascular smooth muscle contraction	115	0.48	1.85	2.07E-03
Wnt signaling pathway	149	0.45	1.83	2.58E-03
Hematopoietic cell lineage	85	0.49	1.83	2.60E-03
Mapk signaling pathway	266	0.43	1.82	2.59E-03
Intestinal immune network for iga production	46	0.54	1.82	2.70E-03
Pathways in cancer	324	0.42	1.80	3.61E-03
TGF beta signaling pathway	85	0.48	1.79	4.06E-03
Graft versus host disease	37	0.54	1.78	4.21E-03
O glycan biosynthesis	27	0.58	1.74	6.86E-03
Aldosterone regulated sodium reabsorption	42	0.52	1.71	8.95E-03
Cardiac muscle contraction	73	0.46	1.69	1.10E-02
Asthma	28	0.54	1.68	1.15E-02
Long term potentiation	69	0.46	1.66	1.44E-02
Amyotrophic lateral sclerosis	52	0.45	1.55	4.17E-02
Nitrogen metabolism	23	0.52	1.54	4.24E-02

Note: Size: Total number of genes in the category; ES: enrichment score; NES: normalized enrichment score; FDR: false discovery rate.